Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)
Phase II Study of Nanocurcumin Versus Placebo for Patients Undergoing Radiotherapy for Prostate Cancer
There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.
120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
Inclusion Criteria: Histologically confirmed adenocarcinoma of the prostate Candidate for External Beam Radiotherapy ECOG performance status 0-2 Exclusion Criteria: Patients with Metastatic Prostate Cancer Patients with Kidney & Liver dysfunction Gastrointestinal disorders such as IBD, reflux and peptic ulcers Any adverse reaction to curcumin